Skip to content

Genetics of Prostate Cancer in Young Patients

Genetics of Prostate Cancer in Young Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06714227
Acronym
ProK55
Enrollment
50
Registered
2024-12-03
Start date
2023-09-25
Completion date
2024-09-30
Last updated
2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Carcinoma

Brief summary

The aim of the study is to identify genetic variants in genes responsible or potentially responsible for the etiology of prostate cancer in a population of patients with early onset of the malignancy.

Detailed description

The data collected from the study will provide a preliminary picture of the prevalence and type of germline pathological variants in the context of early-onset prostate cancer in the Italian population. In addition, alterations in DNA repair genes other than BRCA1-2 and ATM, including any genes yet undescribed as causative or predisposing, have yet to be explored in detail: in many cases the significance of variants is not well defined in terms of pathogenicity, prognostic value, and predictive indicator of response to different treatments. Therefore, an extensive mutational analysis-even if performed on a limited number of patients-can generate a large number of variants for evaluation, bringing knowledge about the relationship between these variants and the onset of malignancy The information obtained, although merely exploratory, may indicate the desirability of conducting systematic genetic investigations in this particular patient population in the future, especially in view of the new therapeutic strategies available such as immunotherapy or PARP inhibitors

Interventions

GENETICMolecular analysis of genomic DNA (exome sequencing) from peripheral blood sample

The first level of investigation will focus on genes already described in cases of pathogenic germline variants of prostate cancer and/or DNA repair system genes. The second level of investigation will consider variants in genes known to confer increased risk of cancer development, e.g., genes listed in the UK health system's solid tumor predisposition gene panel. Finally, pathogenic/probably pathogenic variants in the exome in genes attributable to increased risk will be evaluated on the basis of molecular pathway and findings in the scientific literature.

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Patients with histologic or cytologic diagnosis of prostate cancer * Age ≥18 years and ≤55 years at first diagnosis of prostate carcinoma * Availability of clinical and instrumental data related to prostate cancer * Patients who knowingly express willingness to participate in the study after signing written informed consent

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Presence/absence and type of pathogenic/probably pathogenic germline variants in genes previously implicated in prostate cancer etiology4 yearsmolecular analysis of genomic DNA

Secondary

MeasureTime frameDescription
Presence/absence and type of variants in genes potentially implicated in the etiology of prostate cancer (candidate genes).4 yearsmolecular analysis of genomic DNA

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026